SAN DIEGO — Inovio Pharmaceuticals (INO in USA), a DNA vaccine developer I sidestepped for four years, is having success with a Middle Eastern virus.
INO shares are raging today.
Inovio’s J, Joseph Kim, via a persistent biz-dev executive, Bernie Hertel, has been on me, professionally, since 2009.
Inovio shares have been raging during most of that span.
This is an INO confessional. It shows why a consuming theme (natural resources) left me in a gully when it comes to making market money.
Further shame: I researched, supported and profited sixfold to eightfold from stakes in two California biomedical companies; before, that is, gold, platinum and the rest possessed me. Those biomeds were San Diego-area Illumina (ILMN in USA) and San Francisco-area Cor Therapeutics. (Not to mention, I have a nephew who is finishing his organic chemistry doctorate at Yale University; my best and longest friend is a highly regarded Boston gastroenterologist with a research, writing and clinical pedigree; more on request.)